{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "claude-opus-4-5",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Tirzepatide 5 mg",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Tirzepatide 5 mg once weekly subcutaneous injection for weight management",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Tirzepatide 10 mg",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Tirzepatide 10 mg once weekly subcutaneous injection for weight management",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Tirzepatide 15 mg",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Tirzepatide 15 mg once weekly subcutaneous injection for weight management",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Placebo",
        "role": {
          "code": "Placebo",
          "codeSystem": "USDM",
          "decode": "Placebo"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo once weekly subcutaneous injection",
        "administrationIds": [
          "admin_4"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Tirzepatide (LY3298176)",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Injection",
          "codeSystem": "USDM",
          "decode": "Injection"
        },
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "prod_2",
        "name": "Placebo",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Injection",
          "codeSystem": "USDM",
          "decode": "Injection"
        },
        "strength": "Matching placebo",
        "manufacturer": "Eli Lilly and Company"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Tirzepatide 5 mg QW",
        "instanceType": "Administration",
        "dose": "Starting dose 2.5 mg, escalating to 5 mg",
        "doseFrequency": "Once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "id": "admin_2",
        "name": "Tirzepatide 10 mg QW",
        "instanceType": "Administration",
        "dose": "Starting dose 2.5 mg, escalating by 2.5 mg every 4 weeks to 10 mg",
        "doseFrequency": "Once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "id": "admin_3",
        "name": "Tirzepatide 15 mg QW",
        "instanceType": "Administration",
        "dose": "Starting dose 2.5 mg, escalating by 2.5 mg every 4 weeks to 15 mg",
        "doseFrequency": "Once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "id": "admin_4",
        "name": "Placebo QW",
        "instanceType": "Administration",
        "dose": "Matching placebo",
        "doseFrequency": "Once weekly",
        "route": {
          "code": "Subcutaneous",
          "codeSystem": "USDM",
          "decode": "Subcutaneous"
        },
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Tirzepatide",
        "instanceType": "Substance",
        "description": "39-amino acid synthetic peptide dual GIP and GLP-1 receptor agonist with C20 fatty diacid moiety"
      }
    ],
    "medicalDevices": [
      {
        "id": "dev_1",
        "name": "Autoinjector (single-dose pen)",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "id": "dev_2",
        "name": "Autoinjector demonstration device",
        "instanceType": "MedicalDevice",
        "manufacturer": "Eli Lilly and Company"
      }
    ],
    "summary": {
      "interventionCount": 4,
      "productCount": 2,
      "deviceCount": 2
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Tirzepatide 5 mg",
        "role": "Investigational Product",
        "description": "Tirzepatide 5 mg once weekly subcutaneous injection for weight management"
      },
      {
        "name": "Tirzepatide 10 mg",
        "role": "Investigational Product",
        "description": "Tirzepatide 10 mg once weekly subcutaneous injection for weight management"
      },
      {
        "name": "Tirzepatide 15 mg",
        "role": "Investigational Product",
        "description": "Tirzepatide 15 mg once weekly subcutaneous injection for weight management"
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo once weekly subcutaneous injection"
      }
    ],
    "products": [
      {
        "name": "Tirzepatide (LY3298176)",
        "doseForm": "Injection",
        "strength": "2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg",
        "manufacturer": "Eli Lilly and Company"
      },
      {
        "name": "Placebo",
        "doseForm": "Injection",
        "strength": "Matching placebo",
        "manufacturer": "Eli Lilly and Company"
      }
    ],
    "substances": [
      {
        "name": "Tirzepatide",
        "description": "39-amino acid synthetic peptide dual GIP and GLP-1 receptor agonist with C20 fatty diacid moiety"
      }
    ],
    "administrations": [
      {
        "name": "Tirzepatide 5 mg QW",
        "dose": "Starting dose 2.5 mg, escalating to 5 mg",
        "frequency": "Once weekly",
        "route": "Subcutaneous",
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "name": "Tirzepatide 10 mg QW",
        "dose": "Starting dose 2.5 mg, escalating by 2.5 mg every 4 weeks to 10 mg",
        "frequency": "Once weekly",
        "route": "Subcutaneous",
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "name": "Tirzepatide 15 mg QW",
        "dose": "Starting dose 2.5 mg, escalating by 2.5 mg every 4 weeks to 15 mg",
        "frequency": "Once weekly",
        "route": "Subcutaneous",
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      },
      {
        "name": "Placebo QW",
        "dose": "Matching placebo",
        "frequency": "Once weekly",
        "route": "Subcutaneous",
        "duration": "72 weeks (or 176 weeks for participants with prediabetes)"
      }
    ],
    "devices": [
      {
        "name": "Autoinjector (single-dose pen)",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Subcutaneous injection delivery device for tirzepatide or placebo"
      },
      {
        "name": "Autoinjector demonstration device",
        "manufacturer": "Eli Lilly and Company",
        "purpose": "Training device for demonstrating injection technique"
      }
    ]
  }
}